Matthew LorenceCEO at CDR3 Therapeutics Inc., USA
Matthew Lorence has extensive experience in the molecular diagnostic and genomics industries and is currently CEO at CDR3 Therapeutics, a UCLA startup focusing on virus-associated cancers and chronic viral infections. He most recently served as CEO at Concise Separations, as President and CEO of Edge Biosystems, and as SVP, Global Marketing at CalibreScientific. He earned both a PhD degree in Molecular Biology and an MBA degree in Marketing from the University of Texas at Dallas. Dr. Lorence has extensive experience with the FDA with broad knowledge of the CLIA regulations related to the development of LDTs.